Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial

Middle East Journal of Digestive Diseases

Volumn 9, Issue 3, 2017, Pages 151-159

  Behrouz, Vahideh ^a   Jazayeri, Shima ^b   Aryaeian, Naheed ^a   Zahedi, Mohamad Javad ^c   Hosseini, Fatemeh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipokine; Fatty liver; Insulin sensitivity; Prebiotic; Probiotic

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; FRUCTOSE OLIGOSACCHARIDE; GLUCOSE; LEPTIN; MALTODEXTRIN; PROBIOTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STEATOSIS; WEIGHT REDUCTION;

EID: 85047947514     PISSN: 20085230     EISSN: 20085249     Source Type: Journal    
DOI: 10.15171/mejdd.2017.66     Document Type: Article

References (45)

1. Della Corte C, Liccardo D, Mosca A, Vania A, Nobili V. Non-alcoholic fatty liver disease. Paediatr Child Health 2013;23:529-34. doi: 10.1016/j.paed.2013.08.003.
2. Ostad Rahimi A, Mahdavi R, Somi MH, Tarzemani MK. Oxidative stress-related parameters and antioxidant status in non-alcoholic fatty liver disease patients. IJEM 2011;12:493-9.
3. Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin North Am 2014;98:55-72. doi: 10.1016/j. mcna.2013.09.001.
4. Ghaemi A, Taleban F, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, et al. Effect of weight reduction diet on non-alcoholic fatty liver disease. Iran J Nutr Sci Food Technology 2013;8:123-34.
5. Lam B, Younossi ZM. Review: treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. doi: 10.1177/1756283X09359964.
6. Guo H, Zhong R, Liu Y, Jiang X, Tang X, Li Z, et al. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition 2014;30:198-203. doi:10.1016/j.nut.2013.07.023.
7. Eslamparast T, Eghtesad S, Hekmatdoost A, Poustchi H. Probiotics and nonalcoholic fatty liver disease. Middle East J Dig Dis 2013;5:129-36.
8. Daubioul C, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005;59:723-6. doi:10.1038/sj.ejcn.1602127.
9. Compare D, Coccoli P, Rocco A, Nardone O, De Maria S, Cartenì M, et al. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471-6. doi:10.1016/j.nu-mecd.2012.02.007.
10. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19:338-48. doi: 10.1111/1469-0691.12140.
11. Nicolucci AC, Hume MP, Reimer RA. Effect of Prebiotic Fiber Intake on Adiposity and Inflammation in Overweight and Obese Children: Assessing the Role of the Gut Microbiota. Can J Diabetes 2015;39:S43. doi: 10.1016/j.jcjd.2015.01.166.
12. Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol 2013;4:445. doi:10.3389/fimmu.2013.00445.
13. Jakobsdottir G, Nyman M, Fåk F. Designing future prebiotic fiber to target metabolic syndrome. Nutrition 2014;30:497-502. doi:10.1016/j.nut.2013.08.013.
14. Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova TV, Babenko LP, Lazarenko LM, et al. The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J 2014;5:2. doi: 10.1186/1878-5085-5-2.
15. Bernini LJ, Simão ANC, Alfieri DF, Lozovoy MAB, Mari NL, de Souza CHB, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition 2016;32:716-9. doi:10.1016/j.nut.2015.11.001.
16. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes 2014;5:3-17. doi: 10.3920/BM2012.0065.
17. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 2012;32:701-11. doi:10.1111/j.1478-3231.2011.02730.x.
18. Kellow NJ, Coughlan MT, Reid CM. Metabolic ben efits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 2014;111:1147-61. doi: 10.1017/S0007114513003607.
19. Liber A, Szajewska H. Effects of inulin-type fructans on appetite, energy intake, and body weight in children and adults: systematic review of randomized controlled trials. Ann Nutr Metab 2013;63:42-54. doi:10.1159/000350312.
20. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009;7:135-40. doi:10.1016/j.cgh.2008.11.023.
21. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-504. doi:10.1210/jc.2004-2240.
22. National Heart L, and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. National institutes of Heart, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity, 2000.
23. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. doi:10.1007/BF00280883.
24. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10. doi: 10.1210/jcem.85.7.6661.
25. An HM, Park SY, Lee DK, Kim JR, Cha MK, Lee SW, et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 2011;10:116. doi: 10.1186/1476-511X-10-116.
26. Takemura N, Okubo T, Sonoyama K. Lactobacillus plantarum strain No. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med 2010;235:849-56. doi: 10.1258/ebm.2010.009377.
27. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009;89:1751-9. doi: 10.3945/ajcn.2009.27465.
28. Hume M. The Effects of Prebiotic Fibre Intake on Appetite and Body Mass Index z-score in Overweight and Obese Children. (Doctoral dissertation, University of Calgary, 2015).
29. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010;64:636-43. doi:10.1038/ejcn.2010.19.
30. Kishino E, Ito T, Fujita K, Kiuchi Y. A mixture of Salacia reticulata (Kotala himbutu) aqueous extract and cyclo dextrin reduces body weight gain, visceral fat accumulation, and total cholesterol and insulin increases in male Wistar fatty rats. Nutr Res 2009;29:55-63. doi:10.1016/j. nutres.2008.11.001.
31. Sato M, Uzu K, Yoshida T, Hamad EM, Kawakami H, Matsuyama H, et al. Effects of milk fermented by Lactobacillus gasseri SBT2055 on adipocyte size in rats. Br J Nutr 2008;99:1013-7. doi:10.1017/S0007114507839006.
32. Xiong Y, Miyamoto N, Shibata K, Valasek MA, Motoike T, Kedzierski RM, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A 2004;101:1045-50. doi: 10.1073/pnas.2637002100.
33. Genta S, Cabrera W, Habib N, Pons J, Carillo IM, Grau A, et al. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr 2009;28:182-7. doi:10.1016/j.clnu.2009.01.013.
34. Russo F, Riezzo G, Chiloiro M, De Michele G, Chimienti G, Marconi E, et al. Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr pharm des 2010;16:825-31. doi: 10.2174/138161210790883570.
35. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 2013;143:324-31. doi: 10.3945/jn.112.166132.
36. Karimi P, Farhangi MA, Sarmadi B, Gargari BP, Zare Javid A, Pouraghaei M, et al. The therapeutic potential of resistant starch in modulation of insulin resistance, endotoxemia, oxidative stress and antioxidant biomarkers in women with type 2 diabetes: a randomized controlled clinical trial. Ann Nutr Metab 2016;68:85-93. doi: 10.1159/000441683.
37. Abbaszadeh S, Parastouei K, Afshari H, Rostami L, Mahmoudi H, Gamarchehreh M, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr 2016;35:500-5. doi: 10.1080/07315724.2015.1031355.
38. Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-abadi M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013;37:140-8. doi:10.4093/dmj.2013.37.2.140.
39. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013;62:1112-21. doi: 10.1136/gutjnl-2012-303304.
40. Yousefinejad A, Mazloom Z, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci 2013;38:38-43.
41. Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL# 3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm 2014;2014:348959. doi:10.1155/2014/348959.
42. Dehghan P, Gargari BP, Jafar-Abadi MA, Aliasgharzadeh A. Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci Nutr 2014;65:117-23. doi: 10.3109/09637486.2013.836738.
43. Luo J, Van Yperselle M, Rizkalla SW, Rossi F, Bornet FR, Slama G. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 2000;130:1572-7.
44. De Luis D, De la Fuente B, Izaola O, Conde R, Gutiérrez S, Morillo M, et al. Double blind randomized clinical trial controlled by placebo with an alpha linoleic acid and prebiotic enriched cookie on risk cardiovascular factor in obese patients. Nutr Hosp 2011;26:827-33. doi:10.1590/S0212-16112011000400024.
45. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014;99:535-42. doi: 10.3945/ajcn.113.068890.